Fosun Health Capital

The first VC fund established by Fosun Pharma, aiming to invest in innovative drug products and technologies with rapid growth potential at the initial and expansion phases, making full use of our connections with six oversea cooperative VCs, to source world-class and high-quality technologies and products for China markets.

WuXi AppTec

As a global company, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. WuXi AppTec is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Tahoe Venture Capital

Established in 2014, is positioned as a "professional institution for early-stage project investment" and focuses on the fields of healthcare and TMT. It has received continuous support from the Suzhou Municipal Entrepreneurship Investment Guidance Fund and the Suzhou Industrial Park Entrepreneurship Investment Guidance Fund. It has multiple angel funds and PE funds.

Zhuhai Gree Venture Capital

Officially began operations in 2018 as a key state-owned investment platform in Zhuhai. Our primary focus is on early-stage technology innovation investments and managing government-guided funds. As an integral part of Gree Group's equity investment business, we aim to leverage state-owned capital to drive industrial upgrades.

Gree Venture Capital manages several funds, including the Zhuhai Fund Phase III Venture Capital Fund, Hengqin Industrial Development Fund, and Hengqin Angel Investment Fund, with a total managed fund size close to 14 billion RMB.

Ningbo Xinhui Capital

Established in 2020, is positioned as a "professional institution for early-stage project investment" and focuses on the fields of healthcare

ShenZhen Qianhai Quantum

Was estabjlished in July 2022 in Qianhai，Shenzhen, with a registered capital of RMB 80 million. It is a professional investment organisation dedicated to investing in new drug R&D quajlity projects. We adopt the model of CRO business + investment, and are committed to providing a full range of Services for new drug R&D enterprises.